«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 05

Page:

937-941

Research Field:

Publishing date:

Info

Title:

Research progress in organ preservation of intracavitary brachytherapy for locally advanced rectal cancer

Author(s):

CHENG Tian; PENG Ran; QU Ang; WANG Hao

Department of Radiation Oncology,Peking University Third Hospital,Beijing 100191,China.

Keywords:

locally advanced rectal cancer; intracavitary brachytherapy; organ preservation; review literature

PACS:

R735.3+7

DOI:

10.3969/j.issn.1672-4992.2024.05.026

Abstract:

Intracavitary brachytherapy (ICBT) delivers radiation sources into the rectal cavity or near the tumor,providing high-dose,high-efficiency,low-toxicity,and low-cost radiotherapy.This article reviews the clinical efficacy and safety of two types of ICBT in organ preservation treatment for locally advanced rectal cancer (LARC),and discusses the potential advantages and challenges of ICBT in achieving organ preservation and improving patient quality of life.ICBT with or without external beam radiotherapy is an effective means of organ preservation treatment for LARC,but careful selection of suitable patients is still required.

References:

£Û1£ÝSIEGEL RL,WAGLE NS,CERCEK A,et al.Colorectal cancer statistics,2023£ÛJ£Ý.CA Cancer J Clin,2023,73(3):233-254.
£Û2£ÝÖлªÒ½Ñ§»áÖ×Áöѧ·Ö»á, ¹ú¼ÒÎÀÉú½¡¿µÎ¯Ô±»áÒ½Õþ˾.Öйú½áÖ±³¦°©ÕïÁƹ淶(2023°æ)£ÛJ£Ý.ЭºÍҽѧÔÓÖ¾, 2023, 14(4):706-733. General Office of National Health Commission of the People's Republic of China,Oncology Branch of the Chinese Medical Association.The standard for diagnosis and treatment of chinese colorectal cancer£¨2023 version£©£ÛJ£Ý.Medical Journal of Peking Union Medical College Hospital,2023,14(4):706-733.
£Û3£ÝHABR-GAMA A,PEREZ RO,NADALIN W,et al.Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy:long-term results£ÛJ£Ý.Ann Surg,2004,240(4):711-718.
£Û4£ÝSMITH JJ,STROMBOM P,CHOW OS,et al.Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy£ÛJ£Ý.JAMA Oncol,2019,5(4):e185896.

£Û5£ÝDATTANI M,HEALD RJ,GOUSSOUS G,et al.Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer:A systematic review and pooled analysis£ÛJ£Ý.Ann Surg,2018,268(6):955-967.
£Û6£ÝAPPELT AL,PL¢hEN J,VOGELIUS IR,et al.Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy£ÛJ£Ý.International Journal of Radiation Oncology¡¤Biology¡¤Physics,2013,85(1):74-80.
£Û7£ÝPEETERS KC,MARIJNEN CA,NAGTEGAAL ID,et al.The TME trial after a median follow-up of 6 years:increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma£ÛJ£Ý.Ann Surg,2007,246(5):693-701.
£Û8£ÝTAM SY,WU VW.A review on the special radiotherapy techniques of colorectal cancer£ÛJ£Ý.Frontiers in Oncology,2019,9:208.
£Û9£ÝVERRIJSSEN AE,KETELAERS SHJ,RUTTEN HJT,et al.Organ preservation in rectal cancer:an overview of the Dutch perspective and recent developments£ÛJ£Ý.Clin Oncol (R Coll Radiol),2023,35(2):107-116.
£Û10£ÝSUN MYINT A,DHADDA AS,STEWART AJ,et al.The role of contact X-ray brachytherapy in early rectal cancer - who, when and how£ÛJ£Ý.Clinical Oncology,2023,35(2):87-96.
£Û11£ÝG¦IRARD JP,BARBET N,DEJEAN C,et al.Contact X-ray brachytherapy for rectal cancer:past,present,and future£ÛJ£Ý.Cancer/Radioth¨¦rapie,2021,25(8):795-800.
£Û12£ÝCUSTERS PA,GEUBELS BM,HUIBREGTSE IL,et al.Contact X-ray brachytherapy for older or inoperable rectal cancer patients:short-term oncological and functional follow-up£ÛJ£Ý.Cancers (Basel),2021,13(24):6333.
£Û13£ÝGERARD JP,BARBET N,SCHIAPPA R,et al.Neoadjuvant chemoradiotherapy with radiation dose escalation with contact X-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA):a phase 3,randomised controlled trial£ÛJ£Ý.Lancet Gastroenterol Hepatol,2023,8(4):356-367.
£Û14£ÝSUN MYINT A,SMITH FM,GOLLINS S,et al.Dose escalation using contact X-ray brachytherapy after external beam radiotherapy as nonsurgical treatment option for rectal cancer:outcomes from a single-center experience£ÛJ£Ý.Int J Radiat Oncol Biol Phys,2018,100(3):565-573.
£Û15£ÝG¦IRARD JP,BARBET N,GAL J,et al.Planned organ preservation for early T2-3 rectal adenocarcinoma:A french,multicentre study£ÛJ£Ý.Eur J Cancer,2019,108:1-16.
£Û16£ÝSUN MYINT A,SMITH FM,GOLLINS SW,et al.Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation£ÛJ£Ý.Br J Radiol,2017,90(1080):20170175.
£Û17£ÝFRIN AC,EVESQUE L,GAL J,et al.Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients£ÛJ£Ý.Eur J Cancer,2017,72:124-136.
£Û18£ÝSMITH FM,AL-AMIN A,WRIGHT A,et al.Contact radiotherapy boost in association with 'watch and wait' for rectal cancer: initial experience and outcomes from a shared programme between a district general hospital network and a regional oncology centre£ÛJ£Ý.Colorectal Dis,2016,18(9):861-870.
£Û19£ÝDEVIC S,BEKERAT H,GARANT A,et al.Optimization of HDRBT boost dose delivery for patients with rectal cancer£ÛJ£Ý.Brachytherapy,2019,18(4):559-563.
£Û20£ÝJAYAKODY M,JEYASUGITHTHAN J,RAJASOORIYAR C,et al.Dosimetry procedure to verify dose in high dose rate (HDR) brachytherapy treatment of cancer patients:A systematic review£ÛJ£Ý.Phys Med,2022,96:70-80.
£Û21£ÝSAEEDIAN A,LASHKARI M,GHALEHTAKI R,et al.Complication and response assessment of high-dose-rate endorectal brachytherapy boost in neo-adjuvant chemoradiotherapy of locally advanced rectal cancer with long-term outcomes£ÛJ£Ý.J Contemp Brachytherapy,2023,15(2):117-122.
£Û22£ÝGARANT A,VASILEVSKY CA,BOUTROS M,et al.MORPHEUS phase II-III study: a pre-planned interim safety analysis and preliminary results£ÛJ£Ý.Cancers (Basel),2022,14(15):3665.
£Û23£ÝSUN MYINT A,LEE CD,SNEE AJ,et al.High dose rate brachytherapy as a boost after preoperative chemoradiotherapy for more advanced rectal tumours:the clatterbridge experience£ÛJ£Ý.Clin Oncol (R Coll Radiol),2007,19(9):711-719.
£Û24£ÝAPPELT AL,VOGELIUS IR,PL¢hEN J,et al.Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost£ÛJ£Ý.Int J Radiat Oncol Biol Phys,2014,90(1):110-118.
£Û25£ÝGARFINKLE R,LACHANCE S,VUONG T,et al.Is the pathologic response of T3 rectal cancer to high-dose-rate endorectal brachytherapy comparable to external beam radiotherapy£ÛJ£Ý.Dis Colon Rectum,2019,62(3):294-301.
£Û26£ÝHESSELAGER C,VUONG T,P¦FHLMAN L,et al.Short-term outcome after neoadjuvant high-dose-rate endorectal brachytherapy or short-course external beam radiotherapy in resectable rectal cancer£ÛJ£Ý.Colorectal Dis,2013,15(6):662-666.
£Û27£ÝVUONG T,DEVIC S,PODGORSAK E.High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer£ÛJ£Ý.Clin Oncol (R Coll Radiol),2007,19(9):701-705.
£Û28£ÝFOKAS E,GLYNNE-JONES R,FLEISCHMANN M,et al.Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery:lessons from studies in fit patients and future perspectives£ÛJ£Ý.Cancer Treat Rev,2023,112:102490.
£Û29£ÝFLEISCHMANN M,DIEFENHARDT M,TROMMEL M,et al.Image-guided high-dose-rate brachytherapy for rectal cancer:technical note and first clinical experience on an organ-preserving approach£ÛJ£Ý.Strahlenther Onkol,2022,198(7):654-662.
£Û30£ÝCHIANG CL,LEE SF,LEE VW,et al.Toxicity outcome of endorectal brachytherapy boost in medically inoperable patients£ÛJ£Ý.Strahlenther Onkol,2020,196(11):993-997.
£Û31£ÝGARANT A,MAGNAN S,DEVIC S,et al.Image guided adaptive endorectal brachytherapy in the nonoperative management of patients with rectal cancer£ÛJ£Ý.Int J Radiat Oncol Biol Phys,2019,105(5):1005-1011.
£Û32£ÝAPPELT AL,PL¢hEN J,HARLING H,et al.High-dose chemoradiotherapy and watchful waiting for distal rectal cancer:A prospective observational study£ÛJ£Ý.Lancet Oncol,2015,16(8):919-927.
£Û33£ÝCORNER C,BRYANT L,CHAPMAN C,et al.High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma£ÛJ£Ý.Brachytherapy,2010,9(1):66-70.
£Û34£ÝRIJKMANS EC,MARIJNEN CAM,VAN TRIEST B,et al.Predictive factors for response and toxicity after brachytherapy for rectal cancer,results from the HERBERT study£ÛJ£Ý.Radiother Oncol,2019,133:176-182.

Memo

Memo:

±±¾©´óѧµÚÈýÒ½Ôº´´ÐÂת»¯»ù½ð£¨±àºÅ£ºBYSYZHZB2022109£©

Common functions

Last Update: 2024-01-30